NightHawk Biosciences, Inc., (NHWK): Price and Financial Metrics
GET POWR RATINGS... FREE!
NHWK Stock Price Chart Interactive Chart >
NHWK Price/Volume Stats
| Current price | $1.11 | 52-week high | $3.42 |
| Prev. close | $1.11 | 52-week low | $0.75 |
| Day low | $1.08 | Volume | 44,200 |
| Day high | $1.16 | Avg. volume | 51,904 |
| 50-day MA | $1.08 | Dividend yield | N/A |
| 200-day MA | $1.90 | Market Cap | 28.48M |
NightHawk Biosciences, Inc., (NHWK) Company Bio
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Latest NHWK News From Around the Web
Below are the latest news stories about NIGHTHAWK BIOSCIENCES INC that investors may wish to consider to help them evaluate NHWK as an investment opportunity.
NHWK: Shifting Focus to BiomanufacturingBy John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT NightHawk Biosciences, Inc. (NYSE:NHWK) reported third quarter results on November 14, 2022 in a press release and in its Form 10-Q filing. It has been a whirlwind year for the company as it made an acquisition, expanded its manufacturing efforts, converted into a vertically integrated biosciences company and executed several |
NightHawk Biosciences Provides Third Quarter 2022 Business UpdateDURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the third quarter ended September 30, 2022. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “We are continuing to progress our biodefense and biomanufacturing efforts within our Elusys and Scorpion subsidiar |
Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio FacilityDURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that its Scorpion subsidiary plans to host the grand opening of its San Antonio facility today, October 21. David Halverson, President of Scorpion, commented, “We are pleased with the recent FDA feedback regarding our design, operational strategy, and environmental co |
NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) LaboratoryFurther Enhances Research Capabilities in Infectious Disease and BiodefenseDURHAM, N.C., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the construction of an advanced biosafety level 2 (BSL-2) laboratory, adding biodefense and infectious disease capabilities to the Company’s research facilities in Research Triangle Park, North |
NHWK: Scorpion Grand Opening 3Q:22By John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT NightHawk Biosciences, Inc. (NYSE:NHWK) reported second quarter results on August 10, 2022 in a press release and in its Form 10-Q filing. It has been a whirlwind year for the company as it made an acquisition, expanded its manufacturing efforts, converted into a vertically integrated biosciences company and executed several |
NHWK Price Returns
| 1-mo | 11.36% |
| 3-mo | -26.97% |
| 6-mo | -56.22% |
| 1-year | -60.07% |
| 3-year | -36.82% |
| 5-year | -94.06% |
| YTD | 37.87% |
| 2022 | -73.52% |
| 2021 | -43.28% |
| 2020 | 61.20% |
| 2019 | -51.53% |
| 2018 | -74.41% |
Loading social stream, please wait...